Artivion (NYSE:AORT) Cut to “Buy” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Artivion (NYSE:AORT – Free Report) from a strong-buy rating to a buy rating in a research report released on Saturday morning.

A number of other research analysts also recently commented on the stock. Needham & Company LLC upped their price objective on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. JMP Securities lifted their price target on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a report on Friday, October 10th. Finally, Stifel Nicolaus upped their price objective on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.11.

View Our Latest Analysis on AORT

Artivion Stock Up 0.2%

AORT stock opened at $43.10 on Friday. The company has a 50 day moving average price of $45.10 and a two-hundred day moving average price of $42.06. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The stock has a market capitalization of $2.04 billion, a P/E ratio of -179.56 and a beta of 1.59. Artivion has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. The business had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The company’s revenue for the quarter was up 18.9% compared to the same quarter last year. As a group, sell-side analysts expect that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In related news, insider John E. Davis sold 6,563 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $300,979.18. Following the completion of the sale, the insider directly owned 198,842 shares in the company, valued at approximately $9,118,894.12. This represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 34,210 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $1,568,870.60. Following the completion of the sale, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at $36,733,538.98. The trade was a 4.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 234,511 shares of company stock worth $10,612,452. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently modified their holdings of the stock. KBC Group NV acquired a new position in Artivion in the fourth quarter worth about $65,000. State of Alaska Department of Revenue grew its position in shares of Artivion by 7.4% in the 4th quarter. State of Alaska Department of Revenue now owns 25,017 shares of the company’s stock worth $1,140,000 after acquiring an additional 1,723 shares in the last quarter. Sheets Smith Wealth Management acquired a new position in shares of Artivion in the 4th quarter worth approximately $407,000. Silver Oak Securities Incorporated bought a new stake in shares of Artivion in the 4th quarter valued at approximately $306,000. Finally, USA Financial Formulas raised its position in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

See Also